Newsroom - GILUPI GmbH

Pressemitteilungen

Molecular Characterization of Circulating Tumor Cells isolated with GILUPI Technology from Prostate Cancer Patients

, Medizintechnik

GILUPI GmbH announces the recent publication of a clinical study demonstrating multiplex gene expression profiling of circulating tumor cells...

Early lung cancer screening with CTC detection using the GILUPI CellCollector® and Low-Dose Computed Tomography

, Medizintechnik

GILUPI GmbH announces the release of a scientific article about the detection of circulating tumor cells (CTCs) from blood of different groups...

GILUPI will attend at the ACTC congress in Rhodes

, Medizintechnik

GILUPI GmbH is pleased to announce its participation at the 2017 ACTC (Advances in Circulating Tumor Cells) congress. The 3rd ACTC meeting will...

In vivo detection of CTCs in head and neck cancer patients using the GILUPI CellCollector®

, Medizintechnik

GILUPI GmbH announces the recent publication of a clinical study demonstrates the isolation of circulating tumor cells (CTCs) from blood of squamous...

Detection of circulating tumor cells in breast cancer patients using the GILUPI CellCollector®

, Medizintechnik

GILUPI GmbH announces that a scientific article about a multicenter, clinical trial in China has been published in the current issue of "National...

Approval for German Medical Device in China

, Medizintechnik

The GILUPI CellCollector® - the first medical device for in vivo CTC isolation, manufactured by GILUPI - has been approved by the Chinese registrations...

Zulassung für Potsdamer Medizinprodukt in China

, Medizintechnik

Der GILUPI CellCollector® - das erste zugelassene Medizinprodukt zur in vivo – Isolation von zirkulierenden Tumorzellen der Potsdamer GILUPI...

GILUPI extends its patent portfolio

, Medizintechnik

GILUPI GmbH announced today that the company was granted a further Chinese patent protecting the unique and innovative GILUPI technology. The...

Improved detection of circulating tumor cells in prostate cancer patients using the GILUPI CellCollector® in combination with two blood-based assays

, Medizintechnik

GILUPI GmbH announces the release of clinical data from a prostate cancer clinical study in December 2016. The scientific paper demonstrates...

Chinese Biotech Investor VIROAD takes over GILUPI

, Medizintechnik

The investors AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, the - venture capital fund of the Sparkassen of Brandenburg and Business Angels...

Chinesischer Biotechnologie-Investor VIROAD übernimmt GILUPI

, Medizintechnik

Die Investoren AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, der Risikokapitalfonds der Sparkassen des Landes Brandenburg und Business Angels...

GILUPI at the 17th World Conference on Lung Cancer

, Medizintechnik

GILUPI will participate at the 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria. The WCLC is the world’s largest meeting dedicated...

GILUPI at the 6th Herbsttreffen AG Molekularpathologie

, Medizintechnik

At the 6th Herbsttreffen AG Molekularpathologie in Karlsruhe, Germany, from 21th to 22th November 2016, GILUPI will be one of the exhibitors...

Enumeration and molecular characterization of circulating tumor cells in prostate cancer patients using the GILUPI CellCollector®

, Medizintechnik

GILUPI GmbH announces the release of clinical data from a prostate cancer setting in August 2016. The scientific paper demonstrate the isolation...

Identification and enumeration of circulating tumor cells in neuroendocrine tumor patients with GILUPI CellCollector®

, Medizintechnik

GILUPI GmbH announces, that in August 2016 a published scientific paper demonstrated for the first time circulating tumor cell (CTCs) isolation...

Media

Daten werden geladen, bitte warten...
Daten werden geladen, bitte warten...
Daten werden geladen, bitte warten...
Daten werden geladen, bitte warten...
GILUPI GmbH
Hermannswerder 20a
D - 14473 Potsdam




Social-Media Konten

Ansprechpartner

Frau Dr. Claudia Chudak


Marketing & Sales Application Specialist

Telefon +49 331 5818478-5

alle Ansprechpartner

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.


Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.